Skip to main content

The Banker’s Conversation

Billion Pula Bottleneck

In the corridors of Botswana’s public hospitals, the medicine shortage crisis did not emerge overnight. It developed gradually through a combination of procurement challenges, supply chain disruptions, administrative constraints, and market dynamics that have accumulated over several years. By August 2025, when President Duma Boko declared a State of Public Health Emergency, government officials reported that the availability of essential medicines in public health facilities had fallen to critically low levels.

For healthcare workers across the country, the shortages translated into difficult clinical decisions. Doctors and nurses were forced to find alternatives where standard treatments were unavailable, while patients experienced delays in accessing medicines for both chronic and acute conditions. At the same time, policymakers, economists, and procurement specialists began asking difficult questions about whether the structure of Botswana’s pharmaceutical supply chain was sufficiently resilient to serve the public interest.

The Exclusivity Question

At the centre of the debate is Botswana’s reliance on imported medicines. The country has limited domestic pharmaceutical manufacturing capacity and therefore depends heavily on regional and international supply networks to meet healthcare needs.

Within this framework, Exclusive Distribution Agreements (EDAs) have become an increasingly discussed feature of the market. Such agreements are common throughout the global pharmaceutical industry and are not unique to Botswana. Manufacturers frequently appoint specific distributors to represent their products within defined territories, allowing them to manage regulatory compliance, logistics, and market access.

However, some procurement experts argue that these arrangements can reduce sourcing flexibility when governments face urgent supply shortages. Where exclusive rights exist, public buyers may be unable to source directly from manufacturers even when alternative procurement channels appear available.

The challenge is often compounded by regional market structures. Many pharmaceutical manufacturers treat Southern Africa as a single commercial region, appointing regional distributors headquartered outside Botswana. As a result, medicines may pass through several commercial layers before reaching public health facilities.

Government officials and supply chain analysts have argued that these arrangements can increase procurement costs and reduce the state’s bargaining power, particularly during periods of supply stress.

Procurement Costs Under Scrutiny

The public debate has intensified around the cost of medicines and medical commodities purchased through the health system.

Botswana spends approximately P1.1 billion annually on medicines and medical supplies. Recent discussions within government have focused on whether existing procurement arrangements deliver sufficient value for money and whether alternative sourcing models could reduce costs.

President Duma Boko and other government officials have publicly raised concerns about significant price differences between products sourced through traditional channels and those obtained through direct international procurement.

One frequently cited example emerged during emergency procurement exercises conducted during the public health crisis. According to government accounts, estimates obtained through existing procurement channels differed substantially from prices secured through direct sourcing initiatives. Officials have pointed to these differences as evidence that procurement reforms deserve closer examination.

While individual pricing variations require product-by-product verification, the comparisons have become a central reference point in discussions about procurement efficiency, market concentration, and healthcare affordability.

Market Concentration and Future Competition

The structure of Botswana’s pharmaceutical market is also attracting growing attention from economists and competition specialists.

In May 2026, the Competition and Consumer Authority approved a transaction allowing the healthcare group CFAO Healthcare to acquire a controlling interest in Medswana.

The Authority concluded that the transaction was unlikely to substantially lessen competition under applicable competition laws. Nevertheless, some economists and market observers have suggested that increasing vertical integration within pharmaceutical supply chains warrants continued monitoring.

Their concern is not necessarily that competition has been eliminated, but that greater integration between international suppliers and local distributors could influence future market dynamics. Such questions are likely to become increasingly important as Botswana evaluates reforms aimed at strengthening medicine security and reducing supply vulnerabilities.

The Corporate Responsibility Debate

The medicine shortages have also prompted wider discussion about the role of the private sector during national emergencies.

Several companies operating within Botswana’s healthcare sector contributed equipment, supplies, and other forms of assistance during periods of acute shortage. These efforts were welcomed by health authorities and communities alike.

At the same time, civil society groups and some commentators have argued that there may be opportunities for deeper collaboration between government and the private sector to strengthen public health resilience. Suggestions have included emergency donation programmes, public-private partnerships, strategic reserve schemes, and collaborative procurement initiatives.

These proposals remain part of an ongoing policy discussion rather than established obligations on the part of private companies.

When Supply Chain Challenges Reach the Bedside

Beyond procurement policy and market structures lies the reality experienced by patients and healthcare workers.

Health experts have warned that prolonged medicine shortages can increase pressure on hospitals and clinics, disrupt treatment plans, and complicate the management of both chronic and acute illnesses.

Among the concerns frequently cited by healthcare professionals are:

Delays in treatment resulting in longer recovery periods and increased clinical complications.

Greater reliance on alternative medicines where preferred treatments are unavailable.

Increased operational pressure on healthcare workers required to manage shortages.

Additional financial burdens for patients who seek medicines through private providers when public stocks are unavailable.

Experts further caution that prolonged disruptions in access to essential medicines can undermine public confidence in healthcare systems and place additional strain on vulnerable households.

Searching for Solutions

The crisis has accelerated discussion around long-term reforms intended to strengthen the resilience of Botswana’s medicine supply chain.

Among the options under consideration are:

Direct International Procurement

Emergency procurement exercises demonstrated that direct sourcing can provide government with additional flexibility during periods of acute shortage. Policymakers are examining whether elements of this approach can be incorporated into long-term procurement frameworks.

Local Pharmaceutical Manufacturing

Government has expressed interest in attracting pharmaceutical manufacturers to establish operations in Botswana. Advocates argue that local production could reduce dependence on imports, improve supply security, create jobs, and strengthen industrial development.

Regional Procurement Cooperation

Some analysts have proposed expanded regional procurement arrangements that would allow countries to pool demand and negotiate more favourable prices from manufacturers while reducing supply vulnerabilities.

Supply Chain Modernisation

Others point to the need for stronger forecasting systems, inventory management, logistics coordination, and digital tracking mechanisms to ensure medicines reach facilities efficiently once procured.

A System at a Turning Point

The medicine shortages have exposed vulnerabilities within Botswana’s healthcare supply chain and sparked a national conversation about procurement policy, market structure, regulatory oversight, and healthcare resilience.

There remains considerable debate about the relative contribution of procurement rules, supply chain management, market concentration, funding constraints, and broader governance challenges. Different stakeholders continue to offer differing interpretations of the evidence and the most effective path forward.

What is clear, however, is that reliable access to essential medicines remains one of the most pressing public policy challenges facing Botswana’s healthcare system. Whether the solution lies in direct sourcing, local manufacturing, stronger competition, regional procurement partnerships, or a combination of reforms, the objective remains the same: ensuring that patients receive the medicines they need, when they need them, regardless of where they live or what they earn.

The real measure of success will not be found in procurement statistics or policy documents, but in whether Botswana can build a supply chain capable of consistently delivering healthcare outcomes that citizens can trust.

This article draws on public statements by government officials, regulatory decisions, procurement discussions, published reports, and expert commentary. It does not allege criminal wrongdoing by any individual company, distributor, or public official. Many of the issues discussed remain matters of public policy debate, and stakeholders may hold differing views on the causes of the challenges facing Botswana’s healthcare supply chain.